ProjectCV-NCOV-001 – A Phase 1, partially blind, placebo-controlled, dose-esclation, first-in-human, clinical trial to…

Basic data

Acronym:

CV-NCOV-001

Title:

A Phase 1, partially blind, placebo-controlled, dose-esclation, first-in-human, clinical trial to evaluate the safety, reactogenicity and immunogenicity after 1 and 2 doses of the investigational SARS-COV-2 mRNA vaccine CVnCoV administered intramuscularly in healthy adults

Duration:

29/05/2020 to 29/05/2020

Abstract / short description:

Phase 1 trial to test the safety, tolerability and immunogenicity of a COVID-19 vaccine candidate

Keywords:

clinical trial

klinische Studie

COVID-19

SARS-COV-2

Impfstoff